Home / Pharmaceutical / The Pharmaceutical Market: Austria

The Pharmaceutical Market: Austria

Published: Nov 2014 | No Of Pages: 74 | Published By: Espicom

Product Synopsis

The macroenvironment for the Austrian pharmaceutical industry is positive. Economic recovery is strengthening, with modest GDP real growth projected in 2012 and 2013. However, the EIU projects that Austria will be affected by the expected euro zone recession. Legally, laws on intellectual property and patent provision are in line with WTO/TRIPS regulations. Healthcare expenditure has continued its steady growth in recent years. The principal challenge facing the Austrian healthcare system is rising costs. The main reason for this is an ageing population and the uptake of new, more expensive pharmaceuticals. 
Cardiovascular drugs are leaders in the Austrian pharmaceutical market, both in terms of value and volume. Other leading therapeutic areas in terms of value are the nervous system, antineoplastic & immunomodulating agents and alimentary tract & metabolism. In terms of volume, other leading therapeutic areas are the alimentary tract & metabolism, the nervous system and the musculoskeletal system. Meanwhile, the leading OTC product group is cough & cold remedies, followed by vitamins & minerals, pain relievers and stomach & digestion products.
Several multinational pharmaceutical companies have production sites in Austria, including Baxter, Boehringer Ingelheim, Fresenius Kabi, Nycomed and Sandoz. Aside from these, there are also a number of small- and medium-sized pharmaceutical companies, as well as several research-based companies.
Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
BMI Industry View7
Business Environment12
Industry Forecast13
Pharmaceutical Market Forecast13
Table: Pharmaceutical Sales, Historical Data And Forecasts (Austria 2010-2018)14
Healthcare Market Forecast14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2010-2018)16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2010-2018)16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Austria 2010-2018)17
Prescription Drug Market Forecast17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Austria 2010-2018)19
Patented Drug Market Forecast20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Austria 2010-2018)21
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Austria 2010-2018)23
OTC Medicine Forecast24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Austria 2010-2018)25
Macroeconomic Forecasts26
Economic Analysis26
Table: Austria - Economic Activity30
Industry Risk Reward Ratings31
Western Europe Risk/Reward Ratings31
Austria Risk/Reward Ratings36
Market Overview38
Industry Trends And Developments40
Regulatory Development42
Competitive Landscape47
Pharmaceutical Distribution49
Pharmaceutical Wholesale49
Table: Members Of ARGE Pharmazeutika, 201150
Pharmaceutical Retail51
Table: Pharmacy Outlets by Type, 2005-200952
Table: Pharmacy Outlets by State, 2005-200952
Demographic Forecast54
Table: Austria's Population By Age Group, 1990-2020 ('000)55
Table: Austria's population By Age Group, 1990-2020 (% of total)56
Table: Austria's Key Population Ratios, 1990-202057
Table: Austria's Rural And Urban Population, 1990-202057
Pharmaceutical Expenditure Forecast Model60
Healthcare Expenditure Forecast Model60
Notes On Methodology61
Risk/Reward Ratings Methodology62
Ratings Overview63
Table: Pharmaceutical Risk/Reward Ratings Indicators63
Indicator Weightings64
Choose License Type
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +